HOMOERIODICTYOL INHIBITS SURVIVAL AND MIGRATION OF ANDROGEN-RESISTANT PROSTATE CANCER CELLS IN VITRO
DOI:
https://doi.org/10.15407/exp-oncology.2025.01.034Keywords:
homoeriodictyol, docetaxel, PC3, prostate cancer, chemotherapyAbstract
Background. Flavonoids, naturally occurring compounds found in plant-based products, are being investigated as potential non-invasive treatments due to their ability to inhibit cell growth, induce apoptosis, and prevent cell migration. Aim. This study aims to investigate the effects of homoeriodictyol, a member of the flavanone group, both alone and in combination with docetaxel on the survival, apoptosis, migration, and proliferation of prostate cancer cells. Materials and Methods. Androgen-resistant prostate cancer PC3 cells were treated with various concentrations of homoeriodictyol, docetaxel, or a combination of both for 72 h. The treatment effects on cell survival, migration, apoptosis, and gene expression were evaluated using the MTT test, wound healing assay, Hoechst staining, and realtime PCR. Results. Homoeriodictyol induced apoptosis in PC3 cells in a concentration-dependent manner, with a more potent effect in combination with docetaxel. Apoptosis occurred through both intrinsic and extrinsic caspase pathways, leading to the upregulation of CASP3, CASP8, TP53, BAX, and CYCS, and downregulation of BCL2 mRNA expression. Homoeriodictyol also exhibited antimigratory effects via upregulating CDH1, while decreasing CDH2 expression levels. It suppressed epithelial-mesenchymal transition by downregulating the expression of TWIST, SNAIL, and ZEB1, which correlated with the observed antimigratory effects in wound healing assays. Conclusion. Homoeriodictyol exerted potent effects and inhibited prostate cancer cell proliferation and migration, especially when used in combination with docetaxel.
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660
Swiha M, Gafita A, Nguyen A, Emmett L. Treatment response imaging in prostate cancer. PET Clin. 2024;19(3):417- 430. https://doi.org/10.1016/j.cpet.2024.03.009
Daskivich TJ, Naser-Tavakolian A, Gale R, et al. Variation in communication of side effects in prostate cancer treatment consultations. Prostate Cancer Prostatic Dis. 2024;10.1038/s41391-024-00806-2, 10.1038/s41391-024-00806- 2https://doi.org/10.1038/s41391-024-00806-2
Lafontaine ML, Kokorovic A. Cardiometabolic side effects of androgen deprivation therapy in prostate cancer. Curr Opin Support Palliat Care. 2022;16(4):216-222. https://doi.org/10.1097/SPC.0000000000000624
Al-Batran SE, Hozaeel W, Tauchert FK, et al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol. 2015;26(6):1244-1248. https://doi.org/10.1093/an- nonc/mdv129
Turkekul K, Erdogan S. Potent suppression of prostate cancer cell growth and eradication of cancer stem cells by CD44-targeted nanoliposome-quercetin nanoparticles. J Cancer Prev. 2023;28(4):160-174. https://doi.org/10.15430/JCP.2023.28.4.160
Erdogan S, Doganlar O, Doganlar ZB, Turkekul K. Naringin sensitizes human prostate cancer cells to paclitaxel therapy. Prostate Int. 2018;6(4):126-135. https://doi.org/10.1016/j.prnil.2017.11.001
Erdogan S, Doganlar O, Doganlar ZB, et al. The flavonoid apigenin reduces prostate cancer CD44 stem cell survival and migration through PI3K/Akt/NF-κB signaling. Life Sci. 2016;162:77-86. https://doi.org/10.1016/j. lfs.2016.08.019
Genc F, Atabey US, Serttas R, Erdogan S. Abiraterone acetate, in combination with apigenin, attenuates the survival of human castration-sensitive prostate cancer cells. Anticancer Agents Med Chem. 2022;22(18):3148-3156. https:// doi.org/10.2174/1871520622666220426095257
Saquib Q, Ahmed S, Ahmad MS, et al. Anticancer efficacies of persicogenin and homoeriodictyol isolated from.
Process Biochem. 2020;95:186-196. https://doi.org/10.1016/j.procbio.2020.02.008
Anwar S, Malik JA, Ahmed S, et al. Can natural products targeting EMT serve as the future anticancer therapeutics?
Molecules. 2022;27(22):7668. https://doi.org/ARTN 766810.3390/molecules27227668
Albuquerque C, Manguinhas R, Costa JG, et al. A narrative review of the migration and invasion features of non- small cell lung cancer cells upon xenobiotic exposure: insights from studies. Transl Lung Cancer Res. 2021;10(6):2698- 2714. https://doi.org/10.21037/tlcr-21-121
Zhang Y, Han Y, Dong J, et al. Asiaticoside down-regulates HIF-1alpha to inhibit proliferation, migration, and angiogenesis in thyroid cancer cells. Balkan Med J. 2024;41(1):23-29. https://doi.org/10.4274/balkanmedj.gale- nos.2023.2023-7-123
Arul D, Subramanian P. Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Pathol Oncol Res. 2013;19(4):763-770. https://doi.org/10.1007/s12253-013- 9641-1
Albayrak D, Doganlar O, Erdogan S, et al. Naringin combined with NF-kappaB inhibition and endoplasmic reticu- lum stress induces apoptotic cell death via oxidative stress and the PERK/eIF2alpha/ATF4/CHOP axis in HT29 colon cancer cells. Biochem Genet. 2021;59(1):159-184. https://doi.org/10.1007/s10528-020-09996-5
Very Simple IC50 Tool Kit—Calculate, Measure, Determine IC50 Online. http://www.ic50.tk/index.html
Tanagornmeatar K, Chaotham C, Sritularak B, Likhitwitayawuid K, Chanvorachote P. Cytotoxic and anti-meta- static activities of phenolic compounds from Dendrobium ellipsophyllum. Anticancer Res. 2014;34(11):6573-6579.
Ayyildiz A, Koc H, Turkekul K, Erdogan S. Co-administration of apigenin with doxorubicin enhances anti-migra- tion and antiproliferative effects via PI3K/PTEN/AKT pathway in prostate cancer cells. Exp Oncol. 2021;43(2):125- 134. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16096
Nagaprashantha LD, Vatsyayan R, Singhal J, et al. Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem Pharmacol. 2011;82(9):1100-1109. https://doi.org/10.1016/j.bcp.2011.07.078
Yang J, Lin N, Li S, et al. Cannabidiol alleviates oral mucositis by inhibiting PI3K/Akt/NF-kappaB-mediated pyrop- tosis. Balkan Med J. 2024;41(4):286-297. https://doi.org/10.4274/balkanmedj.galenos.2024.2024-2-66
Shao J, Wang C, Li L, et al. Luteoloside inhibits proliferation and promotes intrinsic and extrinsic pathway-me- diated apoptosis involving MAPK and mTOR signaling pathways in human cervical cancer cells. Int J Mol Sci. 2018;19(6):1664. https://doi.org/10.3390/ijms19061664
Whibley C, Pharoah PDP, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95- 107. https://doi.org/10.1038/nrc2584
Boutelle AM, Attardi LD. p53 and tumor suppression: It takes a network. Trends Cell Biol. 2021;31(4):298-310. https://doi.org/10.1016/j.tcb.2020.12.011
Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78-83. https://doi.org/10.1126/science.aah4199
Lu Q, Ji XJ, Zhou YX, et al. Quercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial- mesenchymal transition and renal fibrosis in diabetic nephropathy. Pharmacol Res. 2015;99:237-247. https://doi. org/10.1016/j.phrs.2015.06.006
Cinar AK, Ozal SA, Serttas R, Erdogan S. Eupatilin attenuates TGF-beta2-induced proliferation and epithelial- mesenchymal transition of retinal pigment epithelial cells. Cutan Ocul Toxicol. 2021;40(2):103-114. https://doi.org/ 10.1080/15569527.2021.1902343
De Amicis F, Perri A, Vizza D, et al. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal tran- sition in human thyroid carcinoma cell lines. J Cell Physiol. 2013;228(10):2054-2062. https://doi.org/10.1002/ jcp.24372
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
